Invivyd (IVVD) Cash from Operations Growth (3y) (2024 - 2025)
Invivyd (IVVD) Cash from Operations Growth (3y) (2024 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 34.32% |
| 10 | Invivyd | 104.19 Mn | -122.50 Mn | 16.07 Mn | 31.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.17% |
| Sep 30, 2025 | 47.23% |
| Jun 30, 2025 | 38.58% |
| Mar 31, 2025 | 29.01% |
| Dec 31, 2024 | 19.91% |
| Sep 30, 2024 | 8.84% |
| Jun 30, 2024 | -7.41% |
| Mar 31, 2024 | -28.36% |